CTIS2024-515481-13-00进行中（未招募）1 期
Multicenter clinical trial to evaluate the safety and feasibility of allogeneic tissue engineered product (human nanostructured artificial cornea) in patients with advanced corneal trophic ulcers refractory to (ophtalmic) conventional treatment. - CAH/Ulc/2010
Red Andaluza De Diseno Y Traslacion De Terapias Avanzadas Fundacion Publica Andaluza Progreso Y Salud0 个研究点目标入组 20 人开始时间: 2024年6月25日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Patients that give their informed consent for study participation., Stage 3 Mackie corneal ulcers that do not respond to conventional medical treatment, and may also be secondary to any of the following causes: Riley-Day syndrome (familial dysautonomia), Goldenhar-Gorlin syndrome, Mobius syndrome, Corneal hypoesthesia family, Diabetes, Multiple sclerosis, Leprosy, Hypovitaminosis A, Autoimmune disorders, Acoustic neuroma, Meningioma, Neuralgia, Aneurysm, Stroke, Neoplasia, Herpes simplex, Herpes zoster, Caustication, Wound, inflammation, or wearing contact lenses, Cataract surgery or keratoplasty (aggression to ciliary nerves), Abuse of topical anesthetics, Toxicity of timolol, betaxolol, diclofenac sodium or sulfacetamide, Lattice or granular, Orbital neoplasia., Patients having undergone previous stage 3 Mackie corneal ulcers, currently suffering sequelae such as stromal fibrosis or corneal thinning, having no effective therapeutic alternative., Stromal involvement, not reaching the Descemet membrane. Central or peripheral localization., No active ocular infection., Man or woman aged =18, with no upper age limit., Minimum duration of the disease causing the corneal ulcer: 6 weeks., Patients with normal laboratory parameters as defined by: Leukocytes = 3000, Neutrophils = 1500, Platelets = 100000, AST/ALT = 1.5 ULN, Creatinine = 1.5 mg/dL.
排除标准
- •Absence of stromal involvement., Good response to standard medical treatments for corneal disease in less than 3 to 5 weeks., Active ocular infection., Bullous keratopathy or other endothelial decompensations., Positive serology to HBV, HCV, HIV or any other pathology that may interfere with correct patient follow-up. In the case of HIV, it is understood that a positive serology implies a positive value in the anti-HIV antibody. In the case of HCV, a serology is considered positive when a positive value is obtained for the anti-HCV antibody. Finally, in the case of HBV, positive serology is interpreted as a positive HBV-antigen value or a positive viral load value (HBV-NAT). The inclusion of the subject will not be ruled out if a positive anti-HBVc core antibody is present and the anti-HBVs immunization levels are high enough to guarantee adequate protection of the patient (anti-HBVs > 100 IU/L)., Pregnant or breast-feeding women or childbearing-age women that do not consent the use of contraceptive methods approved in the protocol. Hormonal contraceptive methods that inhibit ovulation (combining estrogens with progestogens or progestogens only) for oral, transdermal, intravaginal, injectable or implantable administration, IUD, surgical sterilization or total abstinence are described as an effective contraceptive method., Medical history of active neoplasia within the past 5 years., Participation in other clinical trials in 3 months previous to inclusion, or in the previous 5 years for trials with advanced therapies.
研究者
相似试验
招募中
2 期
Allogeneic Tissue Engineering (Nanostructured Artificial Human Cornea) in Patients With Corneal Trophic Ulcers in Advanced Stages, Refractory to Conventional (Ophthalmic) Treatment.2024-515481-13-00Red Andaluza De Diseno Y Traslacion De Terapias Avanzadas Fundacion Publica Andaluza Progreso Y Salud20
已完成
不适用
ses of herbal combination by taking it in hot water in covid 19 positive patients.CTRI/2020/07/026631Kumarans fertility centre30
进行中（未招募）
1 期
A multi-centre clinical trial evaluating safety and patients' ability to independently use the medicinal product indicated in the treatment of erectile dysfunctioEUCTR2019-003073-25-PLAdamed Pharma S.A.400
进行中（未招募）
2 期
Therapeutic drug development program for COVID-19JPRN-jRCTs051200049Iwahori Kota42
已完成
不适用
Multicenter study to evaluate efficacy and safety of FINESIA system in dental implant treatment.Single tooth gaps in premolar region, first molar and second molar.JPRN-UMIN000025819Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University40